|Bid||27.40 x 100|
|Day's Range||28.64 - 29.57|
|52 Week Range||24.81 - 33.96|
|PE Ratio (TTM)||-117.49|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
On May 16, we issued an updated research report on Redwood City, CA-based Genomic Health Inc. (GHDX).
Genomic Health, Inc. (GHDX), a global cancer company, recently presented positive results for its Oncotype DX Genomic Prostate Score (GPS) test.
Meanwhile, the genetic-test maker is increasing margins on its way to profitability.